About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Radioligand Therapy Market Size, Demand, Report to 2030

Radioligand Therapy Market

Radioligand Therapy Market Size, Share & Trends Analysis Report By Product (Approved Products, Potential Pipeline), By Indication (Prostate Cancer, Neuroendocrine Tumours (NETs), Others), By Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRHI1832DR
Study Period 2018-2030 CAGR 4.62%
Historical Period 2018-2020 Forecast Period 2022-2030
Base Year 2021 Base Year Market Size USD 10.55 billion
Forecast Year 2030 Forecast Year Market Size USD 15.84 billion
Largest Market North America Fastest Growing Market Europe
Show More
Buy Now
File Formats
The sample report only takes 30 secs to download, no need to wait longer.

Market Segmentation

  1. Radioligand Therapy Market, By Product (2020-2030)
    1. Approved Products
    2. Potential Pipeline
  2. Radioligand Therapy Market, By Indication (2020-2030)
    1. Prostate Cancer
    2. Neuroendocrine Tumours (NETs)
    3. Others
  3. Radioligand Therapy Market, By Biomarker (2020-2030)
    1. Prostate-Specific Membrane Antigen
    2. Ki 67 Expression and Grading
    3. Cytochrome P450 17A1 Inhibitor
    1. North America
      1. North America Radioligand Therapy Market, By Product
        1. Approved Products
          1. Potential Pipeline
          2. North America Radioligand Therapy Market, By Indication
            1. Prostate Cancer
              1. Neuroendocrine Tumours (NETs)
                1. Others
                2. North America Radioligand Therapy Market, By Biomarker
                  1. Prostate-Specific Membrane Antigen
                    1. Ki 67 Expression and Grading
                      1. Cytochrome P450 17A1 Inhibitor
                      2. U.S.
                        1. U.S. Radioligand Therapy Market, By Product
                          1. Approved Products
                            1. Potential Pipeline
                            2. U.S. Radioligand Therapy Market, By Indication
                              1. Prostate Cancer
                                1. Neuroendocrine Tumours (NETs)
                                  1. Others
                                  2. U.S. Radioligand Therapy Market, By Biomarker
                                    1. Prostate-Specific Membrane Antigen
                                      1. Ki 67 Expression and Grading
                                        1. Cytochrome P450 17A1 Inhibitor
                                      2. Canada
                                    2. Europe
                                      1. Europe Radioligand Therapy Market, By Product
                                        1. Approved Products
                                          1. Potential Pipeline
                                          2. Europe Radioligand Therapy Market, By Indication
                                            1. Prostate Cancer
                                              1. Neuroendocrine Tumours (NETs)
                                                1. Others
                                                2. Europe Radioligand Therapy Market, By Biomarker
                                                  1. Prostate-Specific Membrane Antigen
                                                    1. Ki 67 Expression and Grading
                                                      1. Cytochrome P450 17A1 Inhibitor
                                                      2. U.K.
                                                        1. U.K. Radioligand Therapy Market, By Product
                                                          1. Approved Products
                                                            1. Potential Pipeline
                                                            2. U.K. Radioligand Therapy Market, By Indication
                                                              1. Prostate Cancer
                                                                1. Neuroendocrine Tumours (NETs)
                                                                  1. Others
                                                                  2. U.K. Radioligand Therapy Market, By Biomarker
                                                                    1. Prostate-Specific Membrane Antigen
                                                                      1. Ki 67 Expression and Grading
                                                                        1. Cytochrome P450 17A1 Inhibitor
                                                                      2. Germany
                                                                      3. France
                                                                      4. Spain
                                                                      5. Italy
                                                                      6. Russia
                                                                      7. Nordic
                                                                      8. Benelux
                                                                      9. Rest of Europe
                                                                    2. APAC
                                                                      1. APAC Radioligand Therapy Market, By Product
                                                                        1. Approved Products
                                                                          1. Potential Pipeline
                                                                          2. APAC Radioligand Therapy Market, By Indication
                                                                            1. Prostate Cancer
                                                                              1. Neuroendocrine Tumours (NETs)
                                                                                1. Others
                                                                                2. APAC Radioligand Therapy Market, By Biomarker
                                                                                  1. Prostate-Specific Membrane Antigen
                                                                                    1. Ki 67 Expression and Grading
                                                                                      1. Cytochrome P450 17A1 Inhibitor
                                                                                      2. China
                                                                                        1. China Radioligand Therapy Market, By Product
                                                                                          1. Approved Products
                                                                                            1. Potential Pipeline
                                                                                            2. China Radioligand Therapy Market, By Indication
                                                                                              1. Prostate Cancer
                                                                                                1. Neuroendocrine Tumours (NETs)
                                                                                                  1. Others
                                                                                                  2. China Radioligand Therapy Market, By Biomarker
                                                                                                    1. Prostate-Specific Membrane Antigen
                                                                                                      1. Ki 67 Expression and Grading
                                                                                                        1. Cytochrome P450 17A1 Inhibitor
                                                                                                      2. Korea
                                                                                                      3. Japan
                                                                                                      4. India
                                                                                                      5. Australia
                                                                                                      6. Taiwan
                                                                                                      7. South East Asia
                                                                                                      8. Rest of Asia-Pacific
                                                                                                    2. Middle East and Africa
                                                                                                      1. Middle East and Africa Radioligand Therapy Market, By Product
                                                                                                        1. Approved Products
                                                                                                          1. Potential Pipeline
                                                                                                          2. Middle East and Africa Radioligand Therapy Market, By Indication
                                                                                                            1. Prostate Cancer
                                                                                                              1. Neuroendocrine Tumours (NETs)
                                                                                                                1. Others
                                                                                                                2. Middle East and Africa Radioligand Therapy Market, By Biomarker
                                                                                                                  1. Prostate-Specific Membrane Antigen
                                                                                                                    1. Ki 67 Expression and Grading
                                                                                                                      1. Cytochrome P450 17A1 Inhibitor
                                                                                                                      2. UAE
                                                                                                                        1. UAE Radioligand Therapy Market, By Product
                                                                                                                          1. Approved Products
                                                                                                                            1. Potential Pipeline
                                                                                                                            2. UAE Radioligand Therapy Market, By Indication
                                                                                                                              1. Prostate Cancer
                                                                                                                                1. Neuroendocrine Tumours (NETs)
                                                                                                                                  1. Others
                                                                                                                                  2. UAE Radioligand Therapy Market, By Biomarker
                                                                                                                                    1. Prostate-Specific Membrane Antigen
                                                                                                                                      1. Ki 67 Expression and Grading
                                                                                                                                        1. Cytochrome P450 17A1 Inhibitor
                                                                                                                                      2. Turkey
                                                                                                                                      3. Saudi Arabia
                                                                                                                                      4. South Africa
                                                                                                                                      5. Egypt
                                                                                                                                      6. Nigeria
                                                                                                                                      7. Rest of MEA
                                                                                                                                    2. LATAM
                                                                                                                                      1. LATAM Radioligand Therapy Market, By Product
                                                                                                                                        1. Approved Products
                                                                                                                                          1. Potential Pipeline
                                                                                                                                          2. LATAM Radioligand Therapy Market, By Indication
                                                                                                                                            1. Prostate Cancer
                                                                                                                                              1. Neuroendocrine Tumours (NETs)
                                                                                                                                                1. Others
                                                                                                                                                2. LATAM Radioligand Therapy Market, By Biomarker
                                                                                                                                                  1. Prostate-Specific Membrane Antigen
                                                                                                                                                    1. Ki 67 Expression and Grading
                                                                                                                                                      1. Cytochrome P450 17A1 Inhibitor
                                                                                                                                                      2. Brazil
                                                                                                                                                        1. Brazil Radioligand Therapy Market, By Product
                                                                                                                                                          1. Approved Products
                                                                                                                                                            1. Potential Pipeline
                                                                                                                                                            2. Brazil Radioligand Therapy Market, By Indication
                                                                                                                                                              1. Prostate Cancer
                                                                                                                                                                1. Neuroendocrine Tumours (NETs)
                                                                                                                                                                  1. Others
                                                                                                                                                                  2. Brazil Radioligand Therapy Market, By Biomarker
                                                                                                                                                                    1. Prostate-Specific Membrane Antigen
                                                                                                                                                                      1. Ki 67 Expression and Grading
                                                                                                                                                                        1. Cytochrome P450 17A1 Inhibitor
                                                                                                                                                                      2. Mexico
                                                                                                                                                                      3. Argentina
                                                                                                                                                                      4. Chile
                                                                                                                                                                      5. Colombia
                                                                                                                                                                      6. Rest of LATAM

                                                                                                                                                                  Related Reports

                                                                                                                                                                  Global Report
                                                                                                                                                                  The global tool steel market size was valued at USD 5.07 billion in 2021. It is estimated to reach an expected value of USD 8.16 billion by 2030 at a CAGR of 5.3% during the forecast period (2022-2030).  Tool steels are from the carbon ste
                                                                                                                                                                  Buy Now
                                                                                                                                                                  Global Report
                                                                                                                                                                  The global sleep apnea devices market size was valued at USD 4,584.90 million in 2022. It is expected to reach USD 9,405.63 million by 2031, growing at a CAGR of 8.3% during the forecast period (2023–2031). Sleep apnea is a sleeping disorder c
                                                                                                                                                                  Buy Now
                                                                                                                                                                  Global Report
                                                                                                                                                                  The global fire sprinkler market size was valued at USD 12.49 Billion in 2021. It is expected to reach USD 22.26 Billion by 2030, growing at a CAGR of 7.49% during the forecast period (2022–2030). A fire sprinkler system is a straightforward y
                                                                                                                                                                  Buy Now
                                                                                                                                                                  Global Report
                                                                                                                                                                  The global print on demand market was valued at USD 6.3 billion in 2022. It is projected to reach USD 45.6 billion by 2031, growing at a CAGR of 25.3% during the forecast period (2023–2031). E-commerce expansion and the growing trend of online
                                                                                                                                                                  Buy Now
                                                                                                                                                                  Global Report
                                                                                                                                                                  The global platinum market size was valued at USD 7.72 billion in 2022 and is projected to reach USD 11.95 billion by 2031 at a CAGR of 5.13% from 2023 to 2031. Platinum is a crucial component in catalytic converters used to reduce harmful
                                                                                                                                                                  Buy Now

                                                                                                                                                                  Purchase Benefits

                                                                                                                                                                  • Eligible for a free updated report next year
                                                                                                                                                                  • Completely customizable scope
                                                                                                                                                                  • 30% discount on your next purchase
                                                                                                                                                                  • Dedicated account manager
                                                                                                                                                                  • Query resolution within 24 hours
                                                                                                                                                                  • Permission to print the report

                                                                                                                                                                  We are featured on :

                                                                                                                                                                  www.straitsresearch.com
                                                                                                                                                                  © Copyright . All rights Reserved.